Hexima (ASX:HXL) Equity-to-Asset

: 0.96 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Hexima's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$2.55 Mil. Hexima's Total Assets for the quarter that ended in Dec. 2023 was A$2.65 Mil.

The historical rank and industry rank for Hexima's Equity-to-Asset or its related term are showing as below:

ASX:HXL' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36 Med: 0.65 Max: 0.96
Current: 0.96

During the past 7 years, the highest Equity to Asset Ratio of Hexima was 0.96. The lowest was 0.36. And the median was 0.65.

ASX:HXL's Equity-to-Asset is ranked better than
96.55% of 1566 companies
in the Biotechnology industry
Industry Median: 0.66 vs ASX:HXL: 0.96

Hexima Equity-to-Asset Historical Data

The historical data trend for Hexima's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hexima Annual Data

Trend

Jun08

Jun09

Jun10

Jun20

Jun21

Jun22

Jun23

Equity-to-Asset

0.90

0.73

0.36

0.43

0.94

Hexima Semi-Annual Data
	Dec06	Dec07	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Equity-to-Asset											0.60	0.43	0.73	0.94	0.96

Competitive Comparison

For the Biotechnology subindustry, Hexima's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hexima Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Hexima's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Hexima's Equity-to-Asset falls into.

Hexima Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Hexima's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Equity to Asset (A: Jun. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	2.782	/	2.957
	=

Hexima's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	2.545	/	2.651
	=

Hexima (ASX:HXL) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Hexima Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Hexima's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Hexima (ASX:HXL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hexima Ltd (ASX:HXL) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

84-90 Hotham Street, Corporate One, Preston, VIC, AUS, 3072

Website

https://www.hexima.com.au

Hexima Ltd is a biotechnology company. The company is engaged in the research and development of plant-derived proteins and peptides for applications as human therapeutics.